vildagliptin / metformin

This medicine is authorised for use in the European Union.


Eucreas is a diabetes medicine that is used together with diet and exercise to control the blood glucose (sugar) in adults with type 2 diabetes. It is used:  

  • in patients whose blood glucose is insufficiently controlled with metformin taken alone;
  • in patients who are already taking the combination of vildagliptin and metformin as separate tablets;
  • together with other diabetes medicines, including insulin, when these medicines do not provide adequate control of the blood glucose.

Eucreas contains the active substances vildagliptin and metformin hydrochloride.

This EPAR was last updated on 29/03/2023

Authorisation details

Product details
Agency product number
Active substance
  • vildagliptin
  • metformin hydrochloride
International non-proprietary name (INN) or common name
  • vildagliptin
  • metformin
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Vista Building
Elm Park
Merrion Road
Dublin 4

Product information

07/07/2022 Eucreas - EMEA/H/C/000807 - WS2253

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Drugs used in diabetes

  • Combinations of oral blood glucose lowering drugs

Therapeutic indication

Eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:

  • in patients who are inadequately controlled with metformin hydrochloride alone.
  • in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.
  • in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
2 ratings